

**DAFTAR PUSTAKA**

Alejandria, M.M., Lansang, M.D., Dans, L.F., and Mantaring III JBlas. 2013. Intravenous Immunoglobulins for Treating Patients with Severe Sepsis and Septic Shock. **The Cochrane Library**. Anesthesia, Critical and Emergency Care Group

Allangari, A.A. 2008. Intravenous Immunoglobulin Utilization in a Tertiary Care Teaching Hospital in Saudi Arabia. **Saudi Medical Journal**. Vol. 29 No.7, page 477 – 481.

American Academy of Neurology. 2004. Immunotherapy for *Guillain - Barré Syndrome*. **American Academy of Neurology Guideline Summary for Clinicians**. Amerika: American Academy of Neurology.

American Thoracic Society Documents. 2005. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. **American Journal of Respiratory and critical care medicine**., Vol. 171, page 388 – 416.

Andary, M.T., Oleszek, J.L., Maurelus, K., and Mc-Crimmon, R.Y., 2014. *Guillain - Barré Syndrome*. <http://emedicine.medscape.com/article/315632-overview>\_\_\_\_\_diakses tanggal 8 Desember 2014.

Attal, *et al.* 2006. EFNS guidelines on pharmacological treatment of neuropathic pain. **European Journal of Neurology**, Vol.113, Page : 1153 - 1169

Australian Red Cross Blood Service, 2007. Intragam P Product Information. [http://www.csl.com.au/docs/840/200/PT374001001\\_0.pdf](http://www.csl.com.au/docs/840/200/PT374001001_0.pdf) \_\_\_\_\_diakses tanggal 28 juni 2015

Baumann, T.J., and Strickland, J. *In* : Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., and Posey, L.M., (Eds). 2008. **Pharmacotherapy: A Pathophysiologic Approach, Seventh Edition**. New York: The McGraw-Hill Companies, Inc.

Baxter, Karen. *et al.* Eds. 2010. **Stockley's Drug Interactions**. Ninth Edition. London: Pharmaceutical Press. Page 138 – 139; 328 – 329; and 628 – 629.

Berger, Melvin. 2011. Choices in IgG Replacement Therapy for Primary Immune Deficiency Diseases: Subcutaneous IgG vs. Intravenous IgG and Selecting an Optimal Dose. **Current Opinion in Allergy and Clinical Immunology**., Vol. 11, page 532 – 538.

Billeter, M. *In* : Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., and Posey, L.M., 2008. **Pharmacotherapy: A Pathophysiologic Approach, Sixth Edition**. United States of America: The McGraw-Hill Companies, Inc.

Buraga, Ioan., Martin, R.E., Dobrescu, Adrian., and Buraga, Ioana. 2013. Clinical Response to Intravenous Immunoglobulin in Acute Inflammatory Demyelinating Polyradiculoneuropathy. **FARMACIA**, Vol. 61 No. 5, page 957 – 964

Burmester, G.R., Perzutto, A., Ulrichs, T., and Alrich, A., 2003. **Color Atlas of Immunology**. Georg Thieme Verlag, Stuttgart, Germany. Page 236 – 237.

Burns, T.M. 2008. *Guillain - Barré Syndrome*. **Seminars in Neurology**. Vol. 28 No. 2, page 152 – 167.

Chen, B., Yoon, J.S., Hu, B., and Basta, M. 2014. High-dose Intravenous Immunoglobulin Exerts Neuroprotective Effect in the Rat Model of Neonatal Asphyxia. **Pediatric Research**, Vol. 75, No. 5, page 612 – 617

Cipolle, R.J., Strand, L.M., and Morley, P.C., 2012. Chapter 5, Drug Related Problems. In: **Pharmaceutical Care Practice: The patient Centered Management. Third Edition**. New York: Mc-Graw-Hill: 141 – 181.

Departemen Kesehatan Republik Indonesia. 2011. **Peraturan Menteri Kesehatan Republik Indonesia nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik**. Jakarta : Kementerian Kesehatan Republik Indonesia.

Dhadke, S.V., Dhadke, V.N., Bangar, S.S., and Korade, M.B., 2013. *Clinical Profile of Guillain - Barré Syndrome*. **Journal of the Association of Physicians of India.**, Vol. 61, page 168 -172

Duggan, M and Kavanagh, B.P., 2005. Pulmonary Atelecthasis. **Anesthesiology**, Vol. 102, Page : 838 - 854

Elovaara, I., *et al.* 2008. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. **European Journal of Neurology**, Vol. 15, page 893 – 908

Elovaara, I., *et al.* 2012. Chapter 9, Intravenous Immunoglobulin in the Treatment of Neurological Diseases. In: **European Handbook of Neurological Management: Volume 2, Second Edition**. England : Blackwell Publishing: 111 – 127.

European Medicines Agency. 2010. **Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration**, rev 2. London: European Medicines Agency

Fauji, A. 2014. Prosedur Pemeriksaan Muskuloskeletal dan Ekstremitas. <https://www.scribd.com/doc/239137695/PEMFIS-MUSKULOSKELETAL-NEUROLOGI> diakses tanggal 29 juli 2015

Fokke, C., Van den Berg, B., Drenthen, J., Walgaard, C., Van Doorn, P.A., and Jacobs, B.C., 2013. Diagnosis of *Guillain - Barré Syndrome* and Validation of Brighton Criteria. **BRAIN: a journal of neurology**, Vol. 137, page 33 – 43

Feriyawati, Lita. 2005. Anatomi Sistem Saraf dan Peranannya dalam Regulasi Kontraksi Otot Rangka. <http://library.usu.ac.id/download/fk/06001194.pdf> diakses tanggal 21 Desember 2014

GBS/CIDP Foundation International, 2012. *Guillain-Barré Syndrome: An Acute Care Guide For Medical Professionals*. **GBS/CIDP Foundation International 2012 Edition**. Narbeth : The Holly Building

Heryati, Euis dan Faizah, Nur. 2008. Sistem Saraf dalam: **Diktat Kuliah Psikologi Faal**. Fakultas Ilmu Pendidikan. UPI: Bandung. Halaman 2 dan 12

Hoque, M., Nuruzzaman, M., and Malik, M.A. 2013. Comparative Efficacy of Levofloxacin and Ceftriaxone in the Treatment of Community Acquired Pneumonia in Children. **Open Journal of Pediatrics**, Vol. 3, Page : 266 – 269

Hughes, *et al.* 2003. Practice Parameter: Immunotherapy for Guillain-Barre Syndrome. **Lancet**, Vol. 366, page 1653 – 1666

Hughes, R.A.C., and Cronblath, D.R., 2005. Guillain-Barre syndrome. **American Academy of Neurology**, page 736 – 740

Iagaru, N., Cinteza, E., and Cochino, A.V., 2007. Adverse Reactions to Intravenous Immunoglobulin Therapy. **MEDICA: a journal of clinical medicine**, Vol. 2 No.4, page 294 – 298.

Ikatan Apoteker Indonesia. 2010. **ISO Informasi Spesialite Obat Indonesia, Volume 46 – 2011 s/d 2012**. Jakarta : PT ISFI

Inawati. 2010. Sindroma Guillain Barre. <http://elib.fk.uwks.ac.id/asset/archieve/jurnal/SINDROMGUILLAINBARRE.pdf> diakses pada tanggal 26 Oktober 2014.

Israr, Y. A., Juraita dan Rahmat, 2009. Sindroma Guillain-Barre. <http://www.files-of-Drsmmed.tk> diakses pada tanggal 16 Oktober 2014.

Jain, A and Singh, K. 2007. Recent Advances in the Management of Nosocomial Infections. **JK Science**, Vol. 9, No. 1, page 3-8.

Jain, K. K., 2011. **The Handbook of Neuroprotection**. Springer: Humana Press.

Japardi, Iskandar. 2002. Sindrom Guillain Barre. <http://library.usu.ac.id/download/fk/bedah-iskandar-japardi-46.pdf> diakses pada tanggal 16 Oktober 2014.

Jolles, S., Sewell, W.A.C., and Misbah, S.A. 2005. Clinical Uses of Intravenous Immunoglobulin. **Clinical and Experimental Immunology**, Vol. 142, Page : 1 - 11

Kaida, K and Kusunoki, S. 2010. Antibodies to Gangliosides and ganglioside Complexes in *Guillain - Barré Syndrome* and *Fisher Syndrome*: Mini review. **Journal of Neuroimmunology**, Vol. 223, page 5 – 12

Khanifudin, Ahmad. 2012. Organ Pada Sistem Saraf.  
<http://khanifudin.files.wordpress.com/2012/03/sistem-saraf.pdf>  
diakses tanggal 21 Desember 2014

Koleba, T and Ensom, M.H., 2006. Pharmacokinetics of Intravenous Immunoglobulin: A Systemic Review. **Pharmacotherapy** Vol.26, No.6 page 813 – 827

Kroger, A.T and Strikas, R.A., 2014. General Recommendation for Vaccination and Immunoprophylaxis. **Centers for Disease Control and Prevention**. Page 1 – 19

Kuitwaard, *et al.* 2009. Pharmacokinetics of Intravenous Immunoglobulin and Outcome in *Guillain – Barré Syndrome*. **Annals of Neurology**, Vol. 66 page 597-603

Lin, C.S.Y., Krishnan, A.V., Park, S.B., and Kiernan, M.C. 2011. Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. **Archives of Neurology**, Vol. 68, No. 7, page 862 - 869

Liu J, Wang L.N, and McNicol E.D., 2013. Pharmacological treatment for pain in Guillain-Barré syndrome (Review). **Cochrane Database of Systematic Reviews**, Issue 10, Art. No.: CD009950. DOI: 10.1002/14651858. CD009950.pub2.

Lee, David and Bergman, Ulf. 2000. Studies of Drug Utilization. **Pharmacoepidemiology, Fifth Edition**, Wiley – Black Well, Oxford, UK. Page 463

Lepow, M.L and Hughes, P.A., 2007. Infections/Parainfectious Disorders of the Central Nervous System. **In : Guide to the Primary Care of Neurological Disorders, Second Edition. American Association of Neurological Surgeons.**

Masood, Sohail. 2012. Effectiveness of Intravenous Immunoglobulin (IVIG) Therapy in Treatment of Guillain Barre Syndrome. [www.kabafusion.com/IVIG-in-Treatment-of-GBS.html](http://www.kabafusion.com/IVIG-in-Treatment-of-GBS.html) diakses pada tanggal 4 Februari 2015

Meena, A.K., Khadilkar, S.V and Murthy, J.M.K., 2011. Treatment Guidelines for *Guillain - Barré Syndrome*. **Annals of Indian Academy of Neurology**, Vol. 14 (suppl 1): S73 – S81

Misra, I., Temesgen, F.D., Soleiman, N., kalyanam, J., and Kurukumbi, M. 2012. Myasthenia Gravis Presenting Like Guillain – Barre Syndrome. **Case Reports in Neurology**, Vol. 4, Page : 137 - 143

Mori, M., Kuwabara, S., Fukutake, T., and Hattori, T. 2007. Intravenous Immunoglobulin Therapy for Miller Fisher Syndrome. **NEUROLOGY**, Vol. 68, Page : 1144 – 1146

Muid, Masdar. 2005. Manifestasi Klinis dan Laboratoris penderita Sindroma Guillain Barre Di Ruang Perawatan Anak RSUD. Saiful Anwar Malang. **Jurnal kedokteran Brawijaya**, Vol XXI, No.2, p. 90 -96

Nascimento, Y., Carvalho, W., and Acurciu, F., 2009. Drug-Related Problems Observed in a Pharmaceutical Care Service, Belo Horizonte, Brazil. **Brazilian Journal of Pharmaceutical Sciences**, Vol. 45 No.2, page 321 – 330

National Institutes of Health, 2015. Cerebral Spinal Fluid (CSF) Collection. **Medline Plus Medical Encyclopedia**

Netto, A.B., Taly, A.B., Kulkarni, G.B., Rao, G.U., and Rao, S. 2011. Mortality in mechanically ventilated patients of Guillain Barré

Syndrome. **Official Journal of Indian Academy of Neurology**, Vol. 14, Issue. 4, page : 262 - 266

Nugroho. 2013. Anatomi Fisiologi Sistem Saraf.  
<http://staff.unila.ac.id/gnugroho/files/2013/11/ANATOMI-FISIOLOGI-SISTEM-SARAF.pdf> diakses tanggal 21 Desember 2014

Nyati, K.K and Nyati, Roopanshi. 2013. Role of Campylobacter Jejuni Infection in the Pathogenesis of *Guillain – Barré Syndrome*: An Update. **Biomed Research International**. India: Hindawi Publishing Corporation. Page 1 -13

Orbach, H., Katz, U., Sherer, Y., and Shoenfeld, Y. 2005. Intravenous Immunoglobulin: Adverse Effect and Safe Administration. **Clinical Reviews in Allergy & Immunology**, Vol. 29, Issue 3, Page : 173 - 184

Orlikowski, D., *et al.* 2011. *Guillain – Barré Syndrome* following Primary Cytomegalovirus Infection: A Prospective Cohort Study. **Clinical Infectious Disease**, Vol. 52 No.7, page 837 – 844

Palabrica, F. R. R., Kwong, S.L., and Padua, F. R., 2013. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. **Original Article Asia Pacific Allergy**, Vol. 3, page 249 - 256

Pandey, C. K., Raza, M., Tripathi, M., Navkar, D.P., Kumar, A., and Singh, U.K. 2005. The Comparative Evaluation of Gabapentin and Carbamazepine for Pain Management in Guillain – Barre Syndrome Patients in the Intensive Care Unit. **Anesthesia & Analgesia**, Vol. 110, page 220 - 225

Parry, G. J. 2007. Chapter 1, what is Guillain Barre Syndrome. In: **Guillain Barre Syndrome from Diagnosis to Recovery**. American Academy of Neurology (AAN): Demos Medical Publishing: 1 – 8

Pithadia, A. B., and Kakadia, N. 2010. *Guillain – Barre Syndrome* (GBS). **Pharmacological Reports**, Vol. 60, page 220 - 232

Rabinstein, Alejandro A. 2007. Guillain – Barre Syndrome. **The Open General and Internal Medicine Journal**, Vol. 1, page 13 – 22

Robinson, P., Anderson, D., Brouwers, M., Feasby, T.E., and Hume, H. 2007. Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions. **Transfusion Medicine Reviews**, Vol. 21, No. 2, Suppl.1, Page:S3 – S8

Sachdeva. M.P. 2010. Drug Utilization Studies – Scope and Future Perspective. **International Journal on Pharmaceutical and Biological Research**, Vol.1 page 11 – 17

Sangadji, Etta Mamang. 2010. Metodologi Penelitian: **Pendekatan Praktis dalam Penelitian**. Yogyakarta, Penerbit Andi., halaman 189

Scheinfeld, N.S. 2015. Intravenous Immunoglobulin. <http://emedicine.medscape.com/article/210367-overview> diakses tanggal 12 Januari 2015

Sebastian, S. 2012. A Case of Guillain-Barre Syndrome in a Primary Care Setting. **The Journal for Nurse Practition**, Vol. 8, Issue 8, page 643 – 648.

Sederholm, B.H. 2010. *Treatment of Acute Immune – mediated Neuropathies: Guillain - Barré Syndrome and Clinical Variants*. **Seminars of Neurology**, Vol. 30 No.4: 366 – 372

Seneratne, T and Gilbert, C. 2005. Conjunctivitis. **Community Eye Health Journal**, Vol. 18, No. 53, Page : 73 – 75

Shanghai RAAS, 2014. Human Immunoglobulin (pH4) for Intravenous Injection GAMMARAAS. Shanghai RAAS Blood Products Co.,Ltd.

Sharma, S., Sharma, P., and Tyler, L.N. 2011. Transfusion of Blood and Blood Products: Indications and Complications. **American Family Physician**, Vol. 83, No. 6, page : 719 – 724

Snyder, S.D., Polasek, T.M., and Doogue, M.P., 2012. Drug interactions: proniclepa and pracrice. **Australian Prescriber**, Vol 35 No. 3, p. 85



Sun, H., Chow, M.S., and Maderazo, E.G., 1991. Characteristics of Ceftriaxone Binding to Immunoglobulin G and Potential Clinical Significance. **Antimicrobial Agents and Chemotherapy**, Vol. 35, No. 11, Page : 2232 - 2237

Suryana, 2010. Metode Penelitian: **Model Praktis Penelitian Kuantitatif dan Kualitatif**. Jakarta: UPI. Halaman 15

Suwangto, Erfen Gustiawan. 2010. Awas Alergi Obat Akibat Stevens Johnson! Atasi Dengan IGIV. <http://www.sabdaspace.org/node/9135> diakses tanggal 22 januari 2015

Sweetman, S.C (ed). 2009. **Martindale, The Complete Drug Reference, 36<sup>th</sup> edition**. London : The Pharmaceutical Press.

Tam, C.C., Rodriguess, L.C., Peterson, I., and Islam, A., 2006. Incidence of *Guillain – Barré Syndrome* among patient with *Campylobacter* Infection: A General Practice Research Database Study. **The Journal of Infectious Disease** Vol.194, page 95 – 97

Tidy, Colin. 2013. *Guillain - Barré Syndrome*. <http://patient.co.uk/doctor/guillain-barresyndrome-pro> diakses tanggal 8 desember 2014

Tigabu, B.M., Daba, D., and Habte, B. 2014. Drug-Related Problems among Medical Ward Patients in Jimma University Specialized Hospital, Southwest Ethiopia. **Journal of Research in Pharmacy Practice.**, Vol.3, No.1, page 1 – 5

Tsai, C.P, Wang, K.C, Liu, C.Y, Sheng, W.Y and Lee, T.C. 2006. Pharmacoeconomics of Therapy for Guillain – Barre Syndrome: Plasma Exchange and Intravenous Immunoglobulin. **Journal of Clinical Neuroscience**, Vol. 14, page 625 – 629

Van Doorn, P.A, *et al*. 2008. Clinical features, Pathogenesis, and Treatment of *Guillain - Barré Syndrome*. **Lancet Neurology**, Vol. 7; 939 -950

Van Doorn, P.A, *et al.* 2010. IVIg Treatment and Prognosis in *Guillain - Barré Syndrome*. **Journal of Clinical Immunology**, Vol. 30 (suppl 1): 574 – 578

Van Doorn, P.A. 2013. Diagnosis, Treatment and Prognosis *Guillain - Barré Syndrome*. **La Presse Medicale**, Vol. 42: e193 – e201

Van Mill, Foppe. 2005. Drug-Related Problems: A Cornerstone for Pharmaceutical Care. **Journal of the Malta College of Pharmacy Practice**. Issue 10, page 5 – 8

Viktill, K.K and Blix, N.S. 2007. Classification of Drug Related Problems. Topical issues article in **The Journal of the Norwegian Medical Association**, Vol.127, page 3073 – 3076

Wilhems, D.B., *et al.* 2014. Deletion of Prostaglandin E2 Synthesizing Enzymes in Brain Endothelial Cells Attenuates Inflammatory Fever. **The Journal of Neuroscience**, Vol. 34 (35) : 11684 –11690

Winer, J.B. 2010. *Guillain - Barré Syndrome*. Clinical Variants and Their Pathogenesis. **Journal of Neuroimmunology**, Vol. 231, page 70 – 72

Yuki, N and Hartung, H.P. 2012. *Guillain - Barré Syndrome*. **The New England Journal of Medicine**, Vol. 366, page 2294 – 2304